- Home
- KOD vs BUSE Comparison
KOD vs BUSE Comparison
Compare KOD & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | BUSE |
|---|---|---|
| Founded | 2009 | 1868 |
| Country | United States | United States |
| Employees | N/A | 1914 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KOD | BUSE |
|---|---|---|
| Price | $30.52 | $27.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $35.43 | $27.17 |
| AVG Volume (30 Days) | 564.2K | ★ 566.6K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $719,584,000.00 |
| Revenue This Year | N/A | $23.84 |
| Revenue Next Year | N/A | $3.82 |
| P/E Ratio | ★ N/A | $52.77 |
| Revenue Growth | N/A | ★ 55.66 |
| 52 Week Low | $3.43 | $21.63 |
| 52 Week High | $47.84 | $27.78 |
Technical Indicators
Market Signals| Indicator | KOD | BUSE |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 60.22 |
| Support Level | $21.13 | $25.69 |
| Resistance Level | $46.72 | N/A |
| Average True Range (ATR) | 2.52 | 0.50 |
| MACD | -0.54 | 0.05 |
| Stochastic Oscillator | 1.14 | 87.88 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.